Your browser doesn't support javascript.
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Mato, Anthony R; Roeker, Lindsey E; Lamanna, Nicole; Allan, John N; Leslie, Lori; Pagel, John M; Patel, Krish; Osterborg, Anders; Wojenski, Daniel; Kamdar, Manali; Huntington, Scott F; Davids, Matthew S; Brown, Jennifer R; Antic, Darko; Jacobs, Ryan; Ahn, Inhye E; Pu, Jeffrey; Isaac, Krista M; Barr, Paul M; Ujjani, Chaitra S; Geyer, Mark B; Berman, Ellin; Zelenetz, Andrew D; Malakhov, Nikita; Furman, Richard R; Koropsak, Michael; Bailey, Neil; Hanson, Lotta; Perini, Guilherme F; Ma, Shuo; Ryan, Christine E; Wiestner, Adrian; Portell, Craig A; Shadman, Mazyar; Chong, Elise A; Brander, Danielle M; Sundaram, Suchitra; Seddon, Amanda N; Seymour, Erlene; Patel, Meera; Martinez-Calle, Nicolas; Munir, Talha; Walewska, Renata; Broom, Angus; Walter, Harriet; El-Sharkawi, Dima; Parry, Helen; Wilson, Matthew R; Patten, Piers E M; Hernández-Rivas, José-Ángel.
  • Mato AR; Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Roeker LE; Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Lamanna N; Columbia University Medical Center, New York, NY.
  • Allan JN; New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY.
  • Leslie L; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ.
  • Pagel JM; Swedish Cancer Institute, Seattle, WA.
  • Patel K; Swedish Cancer Institute, Seattle, WA.
  • Osterborg A; Karolinska Institute, Solna, Sweden.
  • Wojenski D; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
  • Kamdar M; University of Colorado Cancer Center, Aurora, CO.
  • Huntington SF; Division of Hematology and Oncology, Department of Internal Medicine, Yale University, New Haven, CT.
  • Davids MS; Dana-Farber Cancer Institute, Boston, MA.
  • Brown JR; Dana-Farber Cancer Institute, Boston, MA.
  • Antic D; Clinical Center Serbia, University of Belgrade, Belgrade, Serbia.
  • Jacobs R; Levine Cancer Institute/Atrium Health, Charlotte, NC.
  • Ahn IE; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • Pu J; Upstate Cancer Center, Syracuse, NY.
  • Isaac KM; Emily Couric Clinical Cancer Center, Charlottesville, VA.
  • Barr PM; University of Rochester Wilmot Cancer Institute, Rochester, NY.
  • Ujjani CS; Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Geyer MB; Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Berman E; Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Zelenetz AD; Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Malakhov N; New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY.
  • Furman RR; New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY.
  • Koropsak M; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ.
  • Bailey N; Swedish Cancer Institute, Seattle, WA.
  • Hanson L; Karolinska Institute, Solna, Sweden.
  • Perini GF; Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Ma S; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
  • Ryan CE; Dana-Farber Cancer Institute, Boston, MA.
  • Wiestner A; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • Portell CA; Emily Couric Clinical Cancer Center, Charlottesville, VA.
  • Shadman M; Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Chong EA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA.
  • Brander DM; Division of Hematology and Oncology, Department of Internal Medicine, Duke University School of Medicine, Durham, NC.
  • Sundaram S; Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Seddon AN; Rush University Medical Center, Chicago, IL.
  • Seymour E; Karmanos Cancer Institute, Wayne State University, Detroit, MI.
  • Patel M; Karmanos Cancer Institute, Wayne State University, Detroit, MI.
  • Martinez-Calle N; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
  • Munir T; St James's University Hospital, Leeds, United Kingdom.
  • Walewska R; Royal Bournemouth Hospital, Bournemouth, United Kingdom.
  • Broom A; Western General Hospital, Edinburgh, United Kingdom.
  • Walter H; Leicester Royal Infirmary, Leicester, United Kingdom.
  • El-Sharkawi D; The Royal Marsden Hospital, London, United Kingdom.
  • Parry H; Division of Hematology and Oncology, Department of Internal Medicine, University of Birmingham, Birmingham, United Kingdom.
  • Wilson MR; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
  • Patten PEM; Comprehensive Cancer Centre, King's College, London, United Kingdom.
  • Hernández-Rivas JÁ; Hospital Universitario Infanta Leonor, Madrid, Spain.
Blood ; 136(10): 1134-1143, 2020 09 03.
Article in English | MEDLINE | ID: covidwho-656981
Semantic information from SemMedBD (by NLM)
1. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
2. Chronic Lymphocytic Leukemia PROCESS_OF Patients
Subject
Chronic Lymphocytic Leukemia
Predicate
PROCESS_OF
Object
Patients
3. directive therapy TREATS Chronic Lymphocytic Leukemia
Subject
directive therapy
Predicate
TREATS
Object
Chronic Lymphocytic Leukemia
4. directive therapy TREATS Patients
Subject
directive therapy
Predicate
TREATS
Object
Patients
5. IBTK ASSOCIATED_WITH COVID-19
Subject
IBTK
Predicate
ASSOCIATED_WITH
Object
COVID-19
6. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
7. Chronic Lymphocytic Leukemia PROCESS_OF Patients
Subject
Chronic Lymphocytic Leukemia
Predicate
PROCESS_OF
Object
Patients
8. directive therapy TREATS Chronic Lymphocytic Leukemia
Subject
directive therapy
Predicate
TREATS
Object
Chronic Lymphocytic Leukemia
9. directive therapy TREATS Patients
Subject
directive therapy
Predicate
TREATS
Object
Patients
10. IBTK ASSOCIATED_WITH COVID-19
Subject
IBTK
Predicate
ASSOCIATED_WITH
Object
COVID-19
ABSTRACT
Given advanced age, comorbidities, and immune dysfunction, chronic lymphocytic leukemia (CLL) patients may be at particularly high risk of infection and poor outcomes related to coronavirus disease 2019 (COVID-19). Robust analysis of outcomes for CLL patients, particularly examining effects of baseline characteristics and CLL-directed therapy, is critical to optimally manage CLL patients through this evolving pandemic. CLL patients diagnosed with symptomatic COVID-19 across 43 international centers (n = 198) were included. Hospital admission occurred in 90%. Median age at COVID-19 diagnosis was 70.5 years. Median Cumulative Illness Rating Scale score was 8 (range, 4-32). Thirty-nine percent were treatment naive ("watch and wait"), while 61% had received ≥1 CLL-directed therapy (median, 2; range, 1-8). Ninety patients (45%) were receiving active CLL therapy at COVID-19 diagnosis, most commonly Bruton tyrosine kinase inhibitors (BTKi's; n = 68/90 [76%]). At a median follow-up of 16 days, the overall case fatality rate was 33%, though 25% remain admitted. Watch-and-wait and treated cohorts had similar rates of admission (89% vs 90%), intensive care unit admission (35% vs 36%), intubation (33% vs 25%), and mortality (37% vs 32%). CLL-directed treatment with BTKi's at COVID-19 diagnosis did not impact survival (case fatality rate, 34% vs 35%), though the BTKi was held during the COVID-19 course for most patients. These data suggest that the subgroup of CLL patients admitted with COVID-19, regardless of disease phase or treatment status, are at high risk of death. Future epidemiologic studies are needed to assess severe acute respiratory syndrome coronavirus 2 infection risk, these data should be validated independently, and randomized studies of BTKi's in COVID-19 are needed to provide definitive evidence of benefit.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Leukemia, Lymphocytic, Chronic, B-Cell / Coronavirus Infections Type of study: Controlled clinical trial / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Blood Year: 2020 Document Type: Article

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Leukemia, Lymphocytic, Chronic, B-Cell / Coronavirus Infections Type of study: Controlled clinical trial / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Blood Year: 2020 Document Type: Article